Genmab — Februar 2019
-
Hvis der er rimelighed, skal vi længere nord på, når US er med. Kulturforskellen alene. I DK har vi de senere år fået en bogholderkultur, både med en bogholderagenda blandt politikere, bogholderregering, og bogholderanalytikere. Hvis US holder flaget højt plejer de at belønne de der tør. Og det gør Genmab, på en særdeles solid baggrund. Det hedder ikke omk. det vi taler om som misteltenen. Det hedder investering i højere afkast
-
http://inrater.com/genmab-crowding-out-effekt/ Af Peter Hildebrandt
-
Tak til EL for analysedeling.
-
Peter Hildebrandt er altid skarp.

-
-
-
Han må købe en kasse Heineken og nyde den.
-
-
Subkutan injektion er fremtiden.

-
Fra Davids svar til James Patrick Quigley (JP Morgan) på hans sprøgsmål om guidance/point estimates:
"A lot of the royalties come into Q4 for 2 reasons. One, we've got rising sales numbers quarter-by-quarter as we go throughout the year. But remember, we've got the tranches of royalties that come through. So in Q1, you're going to be starting off again but your royalty income is going to be at the 12% and 13% rising to the 16% and then going through for the last tranche in the fourth quarter the -
then. When we get to that point, you'll be at the 18%."
Så nu kender vi alle royalty-%erne (12, 13, 16, 18, 20) - det eneste vi ikke ved er præcis hvornår 18%-trinnet sætter ind. Men da de andre trin har været fuldstændigt regelmæssige, må man antage at det sidste trin følger samme mønster, altså:
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind